This discovery not only provides new insights into the molecular mechanisms of CCA but also suggests potential targets for the development of innovative treatment strategies, such as drugs targeting LINC00511, YTHDF2, or SOX2 to disrupt this loop and curb tumor progression. Here, SOX2 is linked to cholangiocarcinoma.